552 related articles for article (PubMed ID: 8910274)
1. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
2. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells fight back to beat immune system.
Williams N
Science; 1996 Nov; 274(5291):1302. PubMed ID: 8966600
[No Abstract] [Full Text] [Related]
4. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
5. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
6. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
7. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
Zaks TZ; Chappell DB; Rosenberg SA; Restifo NP
J Immunol; 1999 Mar; 162(6):3273-9. PubMed ID: 10092779
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.
Uzzo RG; Rayman P; Kolenko V; Clark PE; Bloom T; Ward AM; Molto L; Tannenbaum C; Worford LJ; Bukowski R; Tubbs R; Hsi ED; Bander NH; Novick AC; Finke JH
Clin Cancer Res; 1999 May; 5(5):1219-29. PubMed ID: 10353760
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes.
Ferrarini M; Imro MA; Sciorati C; Heltai S; Protti MP; Pellicciari C; Rovere P; Manfredi AA; Rugarli C
Int J Cancer; 1999 May; 81(4):573-9. PubMed ID: 10225447
[TBL] [Abstract][Full Text] [Related]
10. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand-induced apoptosis as a mechanism of immune privilege.
Griffith TS; Brunner T; Fletcher SM; Green DR; Ferguson TA
Science; 1995 Nov; 270(5239):1189-92. PubMed ID: 7502042
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand on tumor cells mediates inactivation of neutrophils.
Chen YL; Chen SH; Wang JY; Yang BC
J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204
[TBL] [Abstract][Full Text] [Related]
13. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
[TBL] [Abstract][Full Text] [Related]
14. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
16. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
17. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
Yang S; Haluska FG
J Immunol; 2004 Apr; 172(7):4599-608. PubMed ID: 15034078
[TBL] [Abstract][Full Text] [Related]
18. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger A; Egle A; Marschitz I; Kos M; Böck G; Ludwig H; Geley S; Kofler R; Greil R
Blood; 1997 Jul; 90(1):12-20. PubMed ID: 9207432
[TBL] [Abstract][Full Text] [Related]
19. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
20. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
